Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic off-th...

Full description

Bibliographic Details
Main Authors: Noelia Maldonado-Pérez, María Tristán-Manzano, Pedro Justicia-Lirio, Elena Martínez-Planes, Pilar Muñoz, Kristina Pavlovic, Marina Cortijo-Gutiérrez, Carlos Blanco-Benítez, María Castella, Manel Juan, Mathias Wenes, Pedro Romero, Francisco J. Molina-Estévez, Concepción Marañón, Concha Herrera, Karim Benabdellah, Francisco Martin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
CAR-T cells
lymphoma
TCRKO
CRISPR/Cas9
off-the-shelf
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1011858/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1011858/full

Similar Items